Apyx Medical (NASDAQ:APYX – Get Rating) and Abiomed (NASDAQ:ABMD – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Institutional and Insider Ownership
65.6% of Apyx Medical shares are owned by institutional investors. Comparatively, 94.5% of Abiomed shares are owned by institutional investors. 11.6% of Apyx Medical shares are owned by company insiders. Comparatively, 2.5% of Abiomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Get Apyx Medical alerts:Risk and Volatility
Apyx Medical has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Apyx Medical and Abiomed, as reported by MarketBeat.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apyx Medical | 0 | 1 | 3 | 0 | 2.75 |
| Abiomed | 0 | 5 | 1 | 0 | 2.17 |
Apyx Medical presently has a consensus target price of $6.00, indicating a potential upside of 72.91%. Abiomed has a consensus target price of $355.60, indicating a potential downside of 6.67%. Given Apyx Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Apyx Medical is more favorable than Abiomed.
Profitability
This table compares Apyx Medical and Abiomed's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Apyx Medical | -39.28% | -39.82% | -31.06% |
| Abiomed | 24.84% | 14.77% | 13.32% |
Earnings and Valuation
This table compares Apyx Medical and Abiomed's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apyx Medical | $48.52 million | 2.47 | -$15.17 million | ($0.56) | -6.20 |
| Abiomed | $1.03 billion | 16.65 | $136.51 million | $5.82 | 65.47 |
Abiomed has higher revenue and earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.
Summary
Abiomed beats Apyx Medical on 10 of the 14 factors compared between the two stocks.
About Apyx Medical
(Get Rating)
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
About Abiomed
(Get Rating)
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.